Table 3 |
|||||
|
Cytokine levels (pg/mL) in patients with PsA stratified by LN |
|||||
|
n (%) of positive patients |
All n = 42 |
LN+ n = 20 (47.6%) |
LN- n = 22 (52.4%) |
Wilcoxon P value |
|
|
|
|||||
|
GM.CSF |
4 (10%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.051 |
|
IFN-γ |
6 (14%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.444 |
|
IL-1β |
7 (7%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.632 |
|
IL-2 |
21 (50%) |
42 (0; 133) |
0 (0; 151) |
83 (0; 119) |
0.851 |
|
IL-4 |
2 (2%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.365 |
|
IL-5 |
19 (19%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.440 |
|
IL-6 |
41 (98%) |
1241 (503; 1,544) |
1324 (764; 1,496) |
1093 (258; 1,720) |
0.462 |
|
IL-10 |
22 (52%) |
4 (0; 13) |
4.4 (0; 12) |
0 (0; 14) |
0.926 |
|
IL-12p70 |
0 |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
NA |
|
IL-13 |
4 (10%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.348 |
|
IL-15 |
38 (91%) |
114 (47; 197) |
180 (109; 261) |
62 (23; 115) |
0.002 |
|
IL-17 |
11 26%) |
0 (0; 20) |
0 (0; 7) |
0 (0; 26) |
0.757 |
|
IL-17F |
12 (29%) |
0 (0; 12) |
0 (0; 6) |
0 (0; 12) |
0.728 |
|
IL-21 |
19 (45%) |
0 (0; 817) |
0 (0; 773) |
0 (0; 958) |
0.591 |
|
IL-22 |
1 (2%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.317 |
|
IL-23 |
15 (36%) |
0 (0; 212) |
0 (0; 190) |
0 (0; 262) |
0.758 |
|
IL-28A |
0 |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
NA |
|
CCL20 |
34 (81%) |
37 (6; 497) |
23 (7; 284) |
40 (1; 624) |
0.752 |
|
TGF-β1 |
8 (19%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 446) |
0.157 |
|
TNF-α |
4 (10%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.323 |
|
TNF-β |
7 (17%) |
0 (0; 0) |
0 (0; 0) |
0 (0; 0) |
0.684 |
|
|
|||||
|
Data are expressed as median (IQR). NA, not applicable. |
|||||
|
Celis et al. Arthritis Research & Therapy 2012 14:R93 doi:10.1186/ar3817 |
|||||
